Radio National Interview: Changing Australia June 2025


Radio National headline

Rare cancers can be extremely difficult to diagnose, and it can take years of misdiagnoses before a culprit is found and patients get adequate treatment.

Meredith Cummins sees this a lot. An oncology nurse for 40 years, she now supports and advocates for sufferers of a set of rare cancers.

And last year, she also helped lead a fierce campaign to have a drug that treats a rare tumour-causing disorder listed on the pharmaceutical benefits scheme. It used to cost $12,000 a month, now it’s just over $30.

Guest: Meredith Cummins is the CEO of NeuroEndocrine Cancer Australia

Credit: Nancy Notzon, Producer


Listen here

Online feedback:

I love this segment! These interviews with such amazing Australians inspire hope and pride!

BRILLIANT WOMAN! Brilliant segment !

I just adore this. Such guests and depth and variety.

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

ANZSNM 56th Annual Conference – Canberra (ACT), Australia

Nurses Workshop, Sunday, 17 May 2026

NECA Canberra NET Patient Forum, Saturday, 16 May 2026

NECA Joins Boehringer Ingelheim Panel Discussion on Clinical Trials and Patient Access

Tax Appeal

Screenshot 2026-05-20 at 2.12.07 PM

Help 31,000+ neuroendocrine cancer patients get the specialised care they deserve.

Every dollar raised is fully tax deductible and helps fund much needed advocacy efforts and patient support.